Proactive Investors - Run By Investors For Investors

ANGLE acquires remaining stake in US subsidiary from Parsortix inventor

Having complete ownership of the US subsidiary is particularly important, said Angle, as it owns core intellectual property related to Parsortix
ANGLE has bought out Hvichia by issuing him with £467,500 worth of shares

ANGLE plc (LON:AGL) now owns 100% of its North American subsidiary after buying out Georgi Hvichia’s 9.47% stake.

Hvichia is the original inventor of ANGLE’s Parsortix cancer detection technology. As such, he still holds a stake in ANGLE North America (ANAI) but the company has issued £467,500 worth of shares to acquire it.

READ: ANGLE finds new angle for cancer detection device

It means that Hvichia, who is currently a director of ANAI but will move to a scientific advisory board member role, now owns 1.08mln ANGLE shares, around 0.76% of the total share capital.

The AIM-quoted firm said the agreement gives it a clean 100% ownership of all its group companies, adding that the US subsidiary is particularly important as it owns core intellectual property related to Parsortix.

“We are pleased to reach an agreement with Georgi Hvichia, the original inventor of the Parsortix microfluidic technology, to acquire his remaining shareholding in our US operating subsidiary in exchange for ANGLE plc shares,” said chief executive Andrew Newland.

Angle shares were untraded at 96.2p in early deals on Monday.

View full AGL profile View Profile

ANGLE PLC Timeline

Related Articles

lung x-ray
May 07 2019
The company has been developing a treatment for chronic lung disease in-house and has partnered with an Australian group to develop a drug for rare liver and lung complaints
man with erectile dysfunction
Headline results from the trial of MED2005 are due before the end of 2019, while Futura is also confident of hearing back from UK regulators about its pain relief gel later in the year
September 18 2018
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use